论文部分内容阅读
目的探讨玻璃体腔注射康柏西普治疗息肉状脉络膜血管病变(PCV)的临床效果。方法回顾性分析2016年1月~2016年12月在潍坊医学院附属医院就诊的27例(27眼)确诊为PCV的患者的临床资料。玻璃体内注射康柏西普,每个月1次,连续注射3个月,必要时追加注射次数。观察患者治疗前后黄斑中心凹厚度以及患眼最佳矫正视力(BCVA)情况对比。结果治疗6个月时,中心凹视网膜厚度明显改善或稳定者占81.5%.治疗后6个月,74.0%患者维持了最佳矫正视力。结论 IVC可以减少PCV患者渗出性改变,并保持患者短期的视觉功能。
Objective To investigate the clinical effect of intravitreal injection of compu to xipu on polypoidal choroidal vasculopathy (PCV). Methods The clinical data of 27 patients (27 eyes) diagnosed as PCV from January 2016 to December 2016 in Weifang Medical College Affiliated Hospital were retrospectively analyzed. Vitreous injection of Compstax, once a month, for 3 consecutive months, if necessary, additional injection times. To observe the patients before and after treatment of foveal thickness and best corrected visual acuity (BCVA) comparison. Results At 6 months, the foveal retinal thickness was significantly improved or stabilized, accounting for 81.5%. Six months after the procedure, 74.0% of the patients maintained the best corrected visual acuity. Conclusion IVC can reduce exudative changes in patients with PCV, and maintain short-term visual function in patients.